Taysha Gene Therapies Inc (TSHA)
2.97
+0.08
(+2.77%)
USD |
NASDAQ |
May 22, 16:00
2.95
-0.02
(-0.67%)
After-Hours: 20:00
Taysha Gene Therapies SG&A Expense (Quarterly): 7.084M for March 31, 2024
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 7.084M |
| December 31, 2023 | 6.719M |
| September 30, 2023 | 8.589M |
| June 30, 2023 | 5.988M |
| March 31, 2023 | 8.751M |
| December 31, 2022 | 7.341M |
| September 30, 2022 | 8.683M |
| June 30, 2022 | 9.867M |
| March 31, 2022 | 11.47M |
| Date | Value |
|---|---|
| December 31, 2021 | 11.81M |
| September 30, 2021 | 11.15M |
| June 30, 2021 | 10.13M |
| March 31, 2021 | 8.236M |
| December 31, 2020 | 6.107M |
| September 30, 2020 | 3.984M |
| June 30, 2020 | 0.948M |
| March 31, 2020 | 0.07M |
| December 31, 2019 | 0.128M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
0.07M
Minimum
Mar 2020
11.81M
Maximum
Dec 2021
7.058M
Average
7.788M
Median
SG&A Expense (Quarterly) Benchmarks
| Aquestive Therapeutics Inc | 10.69M |
| Lifecore Biomedical Inc | 11.69M |
| Relmada Therapeutics Inc | 9.683M |
| ACADIA Pharmaceuticals Inc | 107.99M |
| Cyclacel Pharmaceuticals Inc | 1.582M |